Literature DB >> 31965913

Lessons from precision medicine in rheumatology.

Theresa L Wampler Muskardin1, Jacqueline L Paredes1, Simone Appenzeller2, Timothy B Niewold1.   

Abstract

Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are two common autoimmune rheumatic diseases that vary in severity, clinical presentation, and disease course between individuals. Molecular and genetic studies of both diseases have identified candidate genes and molecular pathways that are linked to various disease outcomes and treatment responses. Currently, patients can be grouped into molecular subsets in each disease, and these molecular categories should enable precision medicine approaches to be applied in rheumatic diseases. In this article, we will review key lessons learned about disease heterogeneity and molecular characterization in rheumatology, which we hope will lead to personalized therapeutic strategies.

Entities:  

Keywords:  Beta-interferon; biomarkers; genetics; immunology; neuromyelitis optica

Mesh：

Year:  2020        PMID： 31965913      PMCID： PMC7727325          DOI： 10.1177/1352458519884249

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


  43 in total

1.  B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels.

Authors:  Lauren L Ritterhouse; Sherry R Crowe; Timothy B Niewold; Joan T Merrill; Virginia C Roberts; Amy B Dedeke; Barbara R Neas; Linda F Thompson; Joel M Guthridge; Judith A James
Journal:  Arthritis Rheum       Date:  2011-12

2.  Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus.

Authors:  Corinna E Weckerle; Beverly S Franek; Jennifer A Kelly; Marissa Kumabe; Rachel A Mikolaitis; Stephanie L Green; Tammy O Utset; Meenakshi Jolly; Judith A James; John B Harley; Timothy B Niewold
Journal:  Arthritis Rheum       Date:  2011-04

3.  Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis.

Authors:  Xuan Feng; Nicholas P Reder; Mounica Yanamandala; Addie Hill; Beverly S Franek; Timothy B Niewold; Anthony T Reder; Adil Javed
Journal:  J Neurol Sci       Date:  2011-10-27       Impact factor: 3.181

4.  Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus.

Authors:  Elena Sanchez; Ajay Nadig; Bruce C Richardson; Barry I Freedman; Kenneth M Kaufman; Jennifer A Kelly; Timothy B Niewold; Diane L Kamen; Gary S Gilkeson; Julie T Ziegler; Carl D Langefeld; Graciela S Alarcón; Jeffrey C Edberg; Rosalind Ramsey-Goldman; Michelle Petri; Elizabeth E Brown; Robert P Kimberly; John D Reveille; Luis M Vilá; Joan T Merrill; Juan-Manuel Anaya; Judith A James; Bernardo A Pons-Estel; Javier Martin; So-Yeon Park; So-Young Bang; Sang-Cheol Bae; Kathy L Moser; Timothy J Vyse; Lindsey A Criswell; Patrick M Gaffney; Betty P Tsao; Chaim O Jacob; John B Harley; Marta E Alarcón-Riquelme; Amr H Sawalha
Journal:  Ann Rheum Dis       Date:  2011-06-30       Impact factor: 19.103

Review 5.  Type I interferon in rheumatic diseases.

Authors:  Theresa L Wampler Muskardin; Timothy B Niewold
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

6.  Twenty-Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis: Results From the Norfolk Arthritis Register.

Authors:  James M Gwinnutt; Deborah P M Symmons; Alexander J MacGregor; Jacqueline R Chipping; Tarnya Marshall; Mark Lunt; Suzanne M M Verstappen
Journal:  Arthritis Rheumatol       Date:  2017-07-10       Impact factor: 10.995

7.  High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus.

Authors:  Vilija Oke; Iva Gunnarsson; Jessica Dorschner; Susanna Eketjäll; Agneta Zickert; Timothy B Niewold; Elisabet Svenungsson
Journal:  Arthritis Res Ther       Date:  2019-04-29       Impact factor: 5.156

8.  Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study.

Authors:  David Isenberg; Gerald B Appel; Gabriel Contreras; Mary A Dooley; Ellen M Ginzler; David Jayne; Jorge Sánchez-Guerrero; David Wofsy; Xueqing Yu; Neil Solomons
Journal:  Rheumatology (Oxford)       Date:  2009-11-20       Impact factor: 7.580

9.  Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.

Authors:  C Potter; K L Hyrich; A Tracey; M Lunt; D Plant; D P M Symmons; W Thomson; J Worthington; P Emery; A W Morgan; A G Wilson; J Isaacs; A Barton
Journal:  Ann Rheum Dis       Date:  2008-03-28       Impact factor: 19.103

10.  Whole-genome sequencing identifies complex contributions to genetic risk by variants in genes causing monogenic systemic lupus erythematosus.

Authors:  Jonas Carlsson Almlöf; Sara Nystedt; Dag Leonard; Maija-Leena Eloranta; Giorgia Grosso; Christopher Sjöwall; Anders A Bengtsson; Andreas Jönsen; Iva Gunnarsson; Elisabet Svenungsson; Lars Rönnblom; Johanna K Sandling; Ann-Christine Syvänen
Journal:  Hum Genet       Date:  2019-02-01       Impact factor: 4.132
View more
  2 in total

Review 1.  Type I interferon in the pathogenesis of systemic lupus erythematosus.

Authors:  Mariana Postal; Jessica F Vivaldo; Ruth Fernandez-Ruiz; Jacqueline L Paredes; Simone Appenzeller; Timothy B Niewold
Journal:  Curr Opin Immunol       Date:  2020-11-24       Impact factor: 7.486

Review 2.  Type I interferon antagonists in clinical development for lupus.

Authors:  Jacqueline L Paredes; Timothy B Niewold
Journal:  Expert Opin Investig Drugs       Date:  2020-09-01       Impact factor: 6.206
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.